BBIO - BridgeBio Pharma, Inc.

QQQ $ 458.93 $ 2.73 (0.6 %)

DIA $ 403.99 $ -1.30 (-0.32 %)

SPY $ 545.82 $ -1.05 (-0.19 %)

TLT $ 100.57 $ -0.13 (-0.13 %)

GLD $ 232.44 $ 0.83 (0.36 %)

Previous Close

$ 29.99

Open

$ 29.31

Bid

$ 28.89 x 229

Ask

$ 29.54 x 127

Day's Range

$ 28.55 - $ 29.47

52 Week Range

$ 21.62 - $ 44.32

Volume

1,421,327

Average Volume

Market Cap

5.64B

Beta (5Y Monthly)

$ 0.96

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-02-2024	03-31-2024	10-Q
3	02-22-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	02-23-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-25-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-11-2020	06-30-2020	10-Q
18	05-14-2020	03-31-2020	10-Q
19	03-03-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

B of A Securities Maintains Buy on BridgeB...
09/11/2024 13:07:24

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $42 price target.

BridgeBio To No Longer Be Pursuing Develop...
09/10/2024 20:51:15

Company is actively seeking partnership opportunities to support future development of BBP-631 or next-generation gene therapie...

BridgeBio Reports Results From Phase 1/2 T...
09/10/2024 20:49:10

BBP-631 has been well tolerated with only mild to moderate treatment-emergent adverse events (TEAEs) and no treatment-related S...

BridgeBio Says FDA Granted Regenerative Me...
09/10/2024 20:46:23

BBP-812 is an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canav...

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:24:13

Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price ...

Piper Sandler Initiates Coverage On Bridge...
09/04/2024 14:37:24

Piper Sandler analyst Biren Amin initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Overweight rating and announces...

vaxcyte-shoals-technologies-polestar-automotive-applied-optoelectronics-and-other-big-stocks-moving-higher-on-tuesday

Vaxcyte, Shoals Technologies, Polestar Aut...
09/03/2024 14:47:56

HC Wainwright & Co. Reiterates Buy on Brid...
09/03/2024 11:40:37

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...

why-is-bridgebio-pharma-stock-trading-higher-on-friday

Why Is BridgeBio Pharma Stock Trading High...
08/30/2024 17:10:49

BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society...

BridgeBio Shares Data On Serum TTR Increas...
08/30/2024 14:54:18

- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (...

marvell-technology-posts-upbeat-sales-joins-mongodb-intel-miniso-group-and-other-big-stocks-moving-higher-on-friday

Marvell Technology Posts Upbeat Sales, Joi...
08/30/2024 14:15:19

alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-heart-muscles

Alnylam Pharmaceuticals Stock Falls After ...
08/30/2024 13:51:46

Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed ...

HC Wainwright & Co. Reiterates Buy on Brid...
08/27/2024 10:15:49

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...

HC Wainwright & Co. Reiterates Buy on Brid...
08/22/2024 11:29:55

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...

JP Morgan Maintains Overweight on BridgeBi...
08/07/2024 18:05:57

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $4...

Evercore ISI Group Maintains Outperform on...
08/07/2024 13:53:35

Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price targ...

HC Wainwright & Co. Reiterates Buy on Brid...
08/05/2024 10:55:16

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...

BridgeBio Pharma Q2 2024 GAAP EPS $(0.39) ...
08/01/2024 12:07:53

BridgeBio Appoints Thomas Trimarchi As Pr...
07/23/2024 11:35:44

Cantor Fitzgerald Reiterates Overweight on...
07/01/2024 12:52:26

Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price ...